Title : Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma.

Pub. Date : 2022

PMID : 35154461






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma. Sorafenib ATP citrate lyase Homo sapiens
2 ACLY expression was higher in sorafenib-resistant cells and HCC-cell sensitivity to sorafenib increased after ACLY-knockout. Sorafenib ATP citrate lyase Homo sapiens
3 ACLY expression was higher in sorafenib-resistant cells and HCC-cell sensitivity to sorafenib increased after ACLY-knockout. Sorafenib ATP citrate lyase Homo sapiens
4 These data suggest that ACLY downregulation can reverse sorafenib resistance, and that SS-PEI can be used to mediate shRNA-ACLY transfection in HCC treatment. Sorafenib ATP citrate lyase Homo sapiens